GEN vs. ALTR, CDAY, SMAR, CCCS, PYCR, ZI, SWI, SVFCX, MTTR, and ZUO
Should you be buying Genesis Healthcare stock or one of its competitors? The main competitors of Genesis Healthcare include Altair Engineering (ALTR), Ceridian HCM (CDAY), Smartsheet (SMAR), CCC Intelligent Solutions (CCCS), Paycor HCM (PYCR), ZoomInfo Technologies (ZI), SolarWinds (SWI), Smead Value C (SVFCX), Matterport (MTTR), and Zuora (ZUO).
Genesis Healthcare vs. Its Competitors
Genesis Healthcare (NYSE:GEN) and Altair Engineering (NASDAQ:ALTR) are both prepackaged software industry companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.
Genesis Healthcare has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Altair Engineering has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Genesis Healthcare presently has a consensus price target of $33.25, indicating a potential upside of 10.47%. Altair Engineering has a consensus price target of $100.83, indicating a potential downside of 9.85%. Given Genesis Healthcare's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genesis Healthcare is more favorable than Altair Engineering.
Genesis Healthcare pays an annual dividend of $0.50 per share and has a dividend yield of 1.7%. Altair Engineering pays an annual dividend of $0.72 per share and has a dividend yield of 0.6%. Genesis Healthcare pays out 55.6% of its earnings in the form of a dividend. Altair Engineering pays out 423.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Genesis Healthcare is clearly the better dividend stock, given its higher yield and lower payout ratio.
82.1% of Genesis Healthcare shares are held by institutional investors. Comparatively, 63.4% of Altair Engineering shares are held by institutional investors. 3.3% of Genesis Healthcare shares are held by company insiders. Comparatively, 21.8% of Altair Engineering shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Genesis Healthcare had 2 more articles in the media than Altair Engineering. MarketBeat recorded 2 mentions for Genesis Healthcare and 0 mentions for Altair Engineering. Genesis Healthcare's average media sentiment score of 0.00 equaled Altair Engineering'saverage media sentiment score.
Genesis Healthcare has higher revenue and earnings than Altair Engineering. Genesis Healthcare is trading at a lower price-to-earnings ratio than Altair Engineering, indicating that it is currently the more affordable of the two stocks.
Genesis Healthcare has a net margin of 17.83% compared to Altair Engineering's net margin of 2.13%. Genesis Healthcare's return on equity of 155.48% beat Altair Engineering's return on equity.
Summary
Genesis Healthcare beats Altair Engineering on 13 of the 17 factors compared between the two stocks.
Get Genesis Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genesis Healthcare Competitors List
Related Companies and Tools
This page (NYSE:GEN) was last updated on 7/8/2025 by MarketBeat.com Staff
